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Age-related macular degeneration (AMD) is the leading cause of new blindness in the western world and is becoming more
of a socio-medical problem as the proportion of the aged population increases. There are multiple eﬀorts underway to better
understand this disease process. AMD involves the abnormal retinal pigment epithelium (RPE), drusen formation, photoreceptor
atrophy, and choroidal neovascularization. Peroxisome proliferator-activated receptors (PPARs) play an important role in lipid
degeneration,immuneregulation,regulationofreactiveoxygenspecies(ROSs),aswellasregulationofvascularendothelialgrowth
factor(VEGF),matrixmetalloproteinase-9(MMP-9),anddocosahexaenoicacid(DHA).Thesemoleculeshaveallbeenimplicated
in the pathogenesis of AMD. In addition, PPAR gamma is expressed in RPE, an essential cell in photoreceptor regeneration and
vision maintenance. This review summarizes the interactions between PPAR, AMD-related molecules, and AMD-related disease
processes.
Copyright © 2008 Alexandra A. Herzlich et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Improvements in public health and medical advancements
have led to increasing lifespan among the population today
and consequently, a mounting burden of many disorders of
deteriorating body systems such as age-related macular de-
generation (AMD). Currently AMD is the leading cause of
blindness in developed countries [1]. With the general aging
of the population, this debilitating disease promises to be-
come an even bigger health care problem. As the demand for
therapy increases, much eﬀort is being directed toward the
elucidation of the mechanisms underlying AMD pathogene-
sis.
Peroxisome proliferator-activated receptors (PPARs) are
members of the steroid/thyroid nuclear receptor superfam-
ily of ligand-activated transcription factors. PPARs are in-
volved in lipid and glucidic metabolism, immune regulation,
and cell diﬀerentiation. Because of these functions, PPARs
and their synthetic agonists have been marketed as ﬁbrates
and thiazolidinediones for hypercholesterolemia and type 2
diabetes mellitus, respectively [2] .T h e r ei sm u c hs p e c u l a -
tion regarding the potential role of PPARs in other disease
mechanisms. Recently, PPARs have been associated with age-
related changes in Alzheimer’s disease [3] and Parkinson’s
disease [4], suggesting that PPARs might also play a role in
the pathogenesis of AMD.
2. AGE-RELATED MACULAR DEGENERATION
The normal aging process of the eye can include a spectrum
of changes in the eyes [5] as follows. Photoreceptors decrease
in density, retinal pigment epithelium (RPE) undergoes loss
of melanin; formation of lipofuscin granules, and accumu-
lation of residual bodies; and basal laminar deposits accu-
mulate in Bruch’s membrane. AMD is a degenerative disease
of the central portion of the retina (the macula) which re-
sults primarily in loss of central vision [6]. The disease can
progress in two diﬀerent ways and, therefore, can be classi-
ﬁed into a dry form (geographic atrophy) and a wet form
(neovascular AMD).
In both subtypes of AMD, the RPE is a crucial cell in the
pathogenesis of AMD [6]. A pivotal function of the RPE is
the phagocytosis of the outer segments of the photoreceptors
and subsequent regeneration of the rods and cones. As one2 PPAR Research
ages, metabolic waste builds up and imposes an increasing
burden on the RPE. The waste, now partially degraded in a
phagolysosome, is visualized histologically as residual bod-
ies and serves as a substrate for lipofuscin formation. These
residual bodies increase in number until they are extruded
and accrue in Bruch’s membrane, thickening the membrane
itself and forming dome shaped basal linear deposits in
Bruch’s membrane referred to as drusen. When the deposits
become large (>125μm in diameter), soft (amorphous and
poorly demarcated), and conﬂuent, they cause interruptions
in the choroidal capillaries, compromising blood ﬂow within
the RPE layer. The extracellular deposits in Bruch’s mem-
brane also instigate chronic inﬂammation, promoting inva-
sion by phagocytes and other immune cells, cytokine release,
a n dp r o d u c t i o no fr e a c t i v eo x y g e ns p e c i e s( R O S s )[ 7].
The retina, because of its high oxygen consumption, its
high levels of cumulative irradiation, and its composition of
polyunsaturated fatty acids, which are readily oxidized and
can initiate a cytotoxic chain reaction, is an ideal environ-
ment for the generation of ROS [8]. Moreover, the process
bywhichRPEphagocytizesisitselfanoxidativestressthatre-
sults in ROS generation. The combined eﬀects from chronic
sustained inﬂammation and ROS generation promote the
development of RPE damage seen in AMD [6, 9, 10]. Thin-
ning or destruction of theRPE leads to its degeneration and
to the subsequent death of rods and cones that depend on
the RPE for their nutrition. This translates into visual loss.
As the RPE degenerates, choriocapillaris beneath the RPE
becomes less fenestrated, reducing the transport of macro-
molecules between the retina and choroidal blood supply
and then disappearing altogether, creating a hypoxic envi-
ronment.Hypoxiathenincreasesthesecretionofgrowthfac-
tors such as vascular endothelial growth factor (VEGF) that
promotes choroidal neovascularization (CNV). The friable,
small vessels comprising CNV are easily damaged and leak,
creating the wet or exudative form of macular degeneration.
The other more-common and less-severe form, termed dry
AMD, occurs in the absence of neovascularization and with
a region of atrophy in a geographic distribution [6].
2.1. RiskfactorsforAMD
The etiology of AMD remains elusive. A major feature of
AMD is its association with age, with the highest preva-
lence among those 85 years of age or older [1]. Other cer-
tain risk factors include smoking and family history or ge-
netics [6, 11–17] .T h e r eh a v eb e e nr e c e n ts t u d i e ss h o w -
ing certain association between AMD and CFH [18–23],
LOC38775/ARMS2 (age-related maculopathy susceptibility
2) [24–27], HrtA-1 [28, 29], and APOE [30–34]genes. Re-
cently, VEGF single nucleotide polymorphism and matrix
metalloproteinases (MMP)-9 microsatellite polymorphism
are reported to be associated with wet AMD [35–37]. Stud-
ies have also considered an association between exposure to
sunlight and AMD [6].
The Age-Related Eye Disease Study (AREDS), a con-
trolled randomized clinical trial reports the use of high doses
of antioxidants (vitamin C, vitamin E, and beta carotene)
and zinc reduce the risk of advanced AMD by about 25%
in patients with moderate risk of developing AMD [38].
Supplementation of various nutrients in the literature have
demonstrated risk reduction for AMD, and these ﬁndings
support the potential role of PPARs in AMD, especially
since diet is an important modiﬁable risk factor when dis-
cussing PPARs, which regulate lipid metabolism and home-
ostasis [39, 40]. PPAR is one of the two characterized types
of polyunsaturated fatty acid-responsive transcriptional fac-
tors. Because humans do not have the capability for de novo
synthesis of essential fatty acids, which are particularly rich
in long-chain polyunsaturated fatty acid (LCPUFA), we are
dependant on dietary sources of these compounds [9]. Im-
portantly, a recent AREDS study has demonstrated that par-
ticipants reporting high-dietary intake of lutein/zeaxanthin,
an LCPUFA which counteracts photochemical damage and
generation of reactive oxygen species that attack cellular
lipids, proteins, and other nuclear material, are statistically
less likely to have advanced AMD (both neovascularizatio-
nand geographic atrophy) or large or extensive interme-
diate drusen than thosereporting lowest dietary intake of
lutein/zeaxanthin [41]. Thus, it is possible that the beneﬁ-
cial eﬀects of lutein/zeaxanthin LCPUFAs are related to their
ability to activate fatty acid-responsive PPARs, suggesting a
protective role of PPARs in AMD pathogenesis.
2.2. Clinicalpresentation
Though the etiology of AMD remains unclear, the clinical
progression of this disease is well characterized. With dry
AMD,patientsmaycomplainofagraduallossofvision,from
several months to years, in one or both eyes due to progres-
sive loss of photoreceptors [42]. This gradual loss of vision
is often ﬁrst noticed as diﬃculty in reading or driving, sco-
tomas,orincreasedrelianceonbrighterlightoramagnifying
lens for tasks that require ﬁne visual acuity [43]. Vision loss
that has occurred acutely over a period of days or weeks may
represent wet AMD due to subretinal/retinal hemorrhage re-
sulting from leakage or breaks of choroidal neovascular ves-
sels. These patients may report an acute distortion in vision
due to retinal hemorrhage, especially distortion of straight
lines, or loss of central vision. Symptoms of wet AMD usu-
ally appear in one eye although AMD pathology is generally
present in both eyes [44].
2.3. Pathologicalﬁndings
The nonneovascular abnormalities in AMD include drusen
as well as abnormalities of the RPE highlighted by accumu-
lation of lipofuscin granules. The main component of lipo-
fuscin is A2E, which is cytotoxic to RPE and induces RPE
apoptosis. Clinically, drusen are round, dull yellow lesions,
located under the sensory neuroretina and RPE, which upon
ﬂuorescein angiography, light up and stain late with no leak-
age. Histologically this material corresponds to the abnor-
malthickening oftheinneraspectofBruch’smembrane.The
thickening involves basal laminar deposits, collagen accumu-
lationbetweentheplasmamembraneoftheRPEcellsandthe
inner aspect of the basement membrane of the RPE, as wellAlexandra A. Herzlich et al. 3
15μm
Figure 1: Microphotograph showing normal human retina stained
for PPARγ in the ganglion cell, inner nuclear layer, outer nuclear
layer, and RPE (avidin-biotin-complex immunoperoxidase).
as basal linear deposits outside the RPE basement membrane
referred to as drusen [6].
How and why drusen develop is unknown, however
much is deduced from its contents. Drusen often have a core
of glycoproteins and their outer domes contain crystallins,
chaperone proteins, apolipoprotein E, vitronectin, proteins
related to inﬂammation (amyloid P, C5, and C5b-9), and
sometimes fragments of RPE cells [45]. Drusen appear as
electron-dense granules within the inner aspect of Bruch’s
membrane. The thickening of the membrane causes a sharp
reduction in ﬂuid and nutrient transport across the mem-
brane. Its diminished function also results in decreased cell
adhesion and anoikis of the photoreceptors, RPE cells, and
possibly choriocapillaris endothelial cells [6]. These deposits
around Bruch’s membrane are also the cause of chronic lo-
cal inﬂammation further promoting AMD development and
progression.
The presence of drusen may lead to RPE degeneration
and subsequently,deterioration of photoreceptors, which are
dependent upon maintenance by RPE [46]. When the atro-
phyofthe RPEandphotoreceptors coversadistinct andcon-
tiguous area, it is termed geographic atrophy. Histologically,
geographic atrophy is characterized by roughly oval patches
of hypopigmentation as a consequence of RPE atrophy. The
underlying choroidal vessels are more readily visible and the
outer retina may appear thin secondary to loss of the pho-
toreceptor and RPE cells. At the periphery of the hypopig-
mented regions there may be hyperpigmented changes from
RPE cell proliferation. If the atrophy is less deﬁned, with a
mottled appearance, then it is called nongeographic atro-
phy. If the disease continues to progress, there comes a point
when the components of the drusen begin to disappear; this
is termed regressed drusen [46]. Additionally there may be
small pinpoint glistening of the drusen where calcium has
been deposited.
ThethirdkeycomponentofAMDischoroidalneovascu-
larization[47].WiththethinninganddestructionoftheRPE
the underlying choriocapillaries become less fenestrated, im-
pairing transport of macromolecules, such as oxygen, be-
tween the retina and choroidal blood supply. The resulting
hypoxia stimulates neovascularization through vascular en-
dothelial growth factor (VEGF). VEGF, which will be dis-
cussed in more detail below, acts as a stimulus for neovascu-
larization[48].Therecanbebothnewvasculargrowthsfrom
the choroidal vessels, growing through Bruch’s membrane
intothesubretinalspace.ClinicallyCNVappearsasapurple-
grey discoloration beneath the retina. With the increase in
blood ﬂow within the retina due to CNV, there may even be
a focal sensory retinal detachment and cystoid edema. New
vessels also promote ﬁbroblast proliferation and disruption
of normal retinal architecture. Moreover, these neovascular
bloodvesselsareextremelyleaky,andhemorrhagefromthese
friable vessels leads to sudden vision loss secondary to ac-
cumulation of ﬂuid or blood in the subretinal space and/or
within the retina itself [49].
3. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS
Peroxisome proliferator-activated receptors (PPARs) seem to
be associated with chronic diseases such as diabetes mellitus,
obesity, atherosclerosis, cancer, and neurodegenerative dis-
eases [2, 4, 50]. Like androgens, steroids, retinoid, and thy-
roid hormone receptors groups, PPARs are members of nu-
clear receptor superfamily of ligand-activated transcription
factors [2]. Though they are among the best-categorized nu-
clear receptor families, the evolution of these molecules re-
mains unclear. PPARs have three known subtypes: α, β,a n d
γ.T h eα subtype is present in adipose tissue, liver, brain,
heart, and skeletal muscle. A synthetic agonist to this sub-
type has been created as a cholesterol-lowering therapy. The
PPAR β subtype, also known as δ or NUC1, is present in
the gut, kidney, brain, and heart. PPARγ, the subtype most
widely studied, is expressed on adipocytes, colon, brain, re-
nal epithelium, monocytes, and macrophages. The γ subtype
is the model for therapy such as thiazolidinediones (trogli-
tazone, rosiglitazone, pioglitazone) for increased insulin sen-
sitivity in noninsulin-dependent diabetes (type 2) [51, 52].
Thisreceptorisalsoexpressedintheretina,speciﬁcallyinthe
RPE and choroidal vascular endothelial cells [53]. Figure 1
shows positive immunoreactivity against PPARγ in the nor-
mal human retina. The association of PPAR with RPE cells,
as well as neuronal cells, supports the hypothesis that PPAR
may play a role in the pathogenesis of AMD; therefore, PPAR
may present a possible target for AMD treatment.
In response to binding by fatty acids, PPARs form
heterodimers with retinoid X receptor (RXR), and the
PPAR-RXR heterodimer binds to speciﬁc response elements
(PPREs) consisting of a direct repeat of the nuclear recep-
tor hexameric DNA core recognition motif spaced by one
nucleotide to inﬂuence the transcription of numerous tar-
get genes [54]. Because PPAR is widely expressed as a tran-
scription factor, it also plays a role in many processes in-
cluding lipid homeostasis, glucose regulation, inﬂammation,
atherosclerosis, ischemia, cancer, and neurodegenerative dis-
eases [2, 36, 37, 54–62] with the subtypes overlapping in ac-
tivity, function, and location.4 PPAR Research
4. PROPOSED MECHANISMS OF AMD AND
THE LINKS TO PPAR
The etiology of AMD is not well understood, an explana-
tion in itself for the various proposed mechanisms for how
and why AMD progresses. Theories include aging, oxidative
stress, endoplasmic reticulum stress, and inﬂammation. In-
terestingly, these processes are shared among diseases with
similar pathophysiological changes to those seen in AMD
and also involve PPAR.
Oxidative stress arises from a signiﬁcant increase in re-
active oxygen species (ROS) concentration and/or a decrease
in detoxiﬁcation mechanisms. ROS include free radicals, hy-
drogen peroxide, and singlet oxygen. There are many natural
sources of oxidative stress such as exposure to environmental
oxidants, ionizing and UV radiation, heat shock, and inﬂam-
mation. The ROSs usually have one or more unpaired elec-
trons in their outer orbits, and in order to achieve a stable
state, extract electrons from other molecules, which them-
selves become unstable, causing a chain reaction [8]. High
levels of oxidative stress exert a toxic eﬀect on biomolecules,
suchasDNA,proteins,andlipids.AsweknowROSmaystart
an oxidative cascade, mediated in part by ROS-induced ac-
tivation of NF-κB, STAT, and AP-1transcription factors, al-
tering the composition of the cellular membrane, changing
proteinconformations,andleadtoanupregulationofproin-
ﬂammatory genes and cytokines, further potentiating dam-
age [62, 63].
Oxidative stress plays a role in ischemic-reperfusion in-
juries, atherosclerosis, hypertension, inﬂammation, cystic ﬁ-
brosis, type 2 diabetes, Alzheimer’s, and Parkinson’s disease
[62]. Oxidative stress has also been linked to aging [64]. The
retina has a very high concentration of lipids [9] and there-
fore easily falls pray to such mechanisms of destruction [8].
Oxidative stress such as aging and light exposure is con-
sidered to be associated with AMD. RPE and photoreceptors
areparticularlysusceptibletooxidativestressbecauseofhigh
oxygen consumption by photoreceptors [8], high concentra-
tion of LCPUFA in the outer segments [65], exposure to vis-
ible light, and presence of lipofuscin, a photo-inducible gen-
erator of ROS in RPE [66, 67]. Clinical data supporting a
beneﬁcial eﬀect of antioxidants in AMD provide direct val-
idation of the role of oxidative injury in AMD treatment.
Subgroup analysis of a multicenter, randomized, placebo-
controlled AREDS trial revealed that an antioxidant cock-
tail of vitamins C and E, β-carotene, and zinc can reduce
the progression of moderate atrophic AMD to late-stage dis-
ease [38]. Epidemiologic data showing that smoking leads to
a signiﬁcantly increased risk of the disease is consistent with
theantioxidantapproachassmokingisknowntodepressan-
tioxidants such as vitamin C and carotenoids, and to induce
hypoxia and ROS generation [68, 69].
PPARs are known to stimulate peroxisome enlargement
a n dp r o l i f e r a t i o n ,a sw e l la su p r e g u l a t i o no fβ-oxidation
enzymes. Since the peroxisome houses a variety of oxida-
tive metabolic processes, they are an obvious cause of ox-
idative stress [64]. Oxidative damage and proinﬂammatory
cytokines, TNF-α,I N F - γ, and MMPs have been cited to
play roles in each of the disease processes mentioned above
[3, 50, 70–74], establishing PPAR as a common link between
them.
Another theory regarding drusen formation involves a
phenomenon known as endoplasmic reticulum (ER) stress.
The ER is central to protein and lipid synthesis and mat-
uration, as most newly formed proteins are assembled in
the ER. Incorrectly folded proteins tend to form aggregates
that are harmful to the cells and thus, ER-resident and/or
visiting chaperone molecules facilitate protein folding and
clearance of terminally misfolded proteins [75]. Any condi-
tion which impairs protein folding, for example, mutations
in proteins that aﬀect folding or ER malfunction, is termed
ER-stress. Increased ER-stress, therefore, leads to protein and
lipid buildup within cells, and this buildup in the eye might
translate into RPE damage and drusen deposition.
The argument for a role for ER stress in AMD patho-
genesis is supported by the well-characterized role of ER
stress in several AMD-related neurodegenerative diseases.
Alzheimer’s disease and Lewy Body diseases, such as Parkin-
son’s disease, are characterized by deposition of abnormal
substances, which may parallel the abnormal deposition of
drusen in the eye. The classical histopathological hallmarks
of Alzheimer’s disease [3, 4] include deposition of ﬁbrillar
amyloid in neuritic plaques as well as intracellular deposits
of hyperphosphorylated tau protein. This results in the for-
mationof neuroﬁbrillary tangles and ﬁnally neuronal death,
causing progressive memory loss and decline in cognitive
functions [4]. In Parkinson’s disease, suﬀering dopaminer-
gic neurons are found to contain Lewy bodies and neurome-
lanin, an end product in catabolism by autoxidation [3]. In
atherosclerosis there are abnormal lipid depositions in blood
vessels leading to plaque formation and partial occlusion of
these vessels [76]. In an AMD model of Ccl2−/−/Cx3cr1−/−
deﬁcient mice abnormal ER protein is detected and associ-
ated with disease pathogenesis [75].
Recent articles have discovered a role for PPAR in ER
stress. Dirkx et al. found that absence of peroxisomes in
hepatocytes had repercussions on diﬀerent subcellular com-
partments, including mitochondria, ER, and lysosomes [77].
Another study found that intracellular calcium mobilization
by PPARγ ligands in rat liver epithelial cells interferes with
proper protein foldingin the ER, thus promoting ER stress
[73]. A third article discovered that under conditions of im-
pairedtranslation,PPARγ ligandsstimulatetheexpressionof
a number of ER stress-responsive genes, such as GADD 153,
BiP, and HSP70 in rat pancreatic β cells. They concluded that
PPARγ ligands induce ER stress [78].
In addition to the obvious parallels, between amyloid,
Lewy bodies, cholesterol, and drusen, there are also similar
processes such as inﬂammation that may play a role in incit-
ing the damage associated with each disease.
Various immunological molecules and inﬂammatory
mediators, cytokines, and chemokines have been identiﬁed
in AMD lesions [79, 80]. Many of them are produced locally
by RPE, choroid, and retina [81]. It has been hypothesized
that RPE dysfunction is the critical event in drusen forma-
tion, making drusen a product of a localized inﬂammatory
response, possibly involving HLA antigens and the comple-
ment system [82]. The hypothesis is based on many diﬀerentAlexandra A. Herzlich et al. 5
ﬁndings scattered among the literature and within diﬀer-
ent ﬁelds of medicine. Drusen, the hallmark of AMD, are
found higher in membranoproliferative glomerulonephritis
II (MPGNII), a complement-medicated immune deﬁciency.
These cuticular drusen are identical, clinically, histologically,
and immunohistochemically to the drusen in AMD [83–
85]. Drusen has also been cited as having similar features
to lipid-laden plaques of atherosclerosis [82, 86]. The rela-
tionship here is inferred from the histological as well as local
inﬂammatory similarities between dysfunctional endothelial
cells and the subendothelial deposition of modiﬁed LDL-
cholesterol in atherosclerotic deposits within arterial vessels
to those of drusen in the eye [86–88]. In addition, molecules
such as MMP-9 seem to be involved in both processes. In-
hibition of MMP-9 in atherosclerotic lesions has been cited
to oppose remodeling, as suggested by the inhibition of inti-
mal thickening and outward arterial remodeling [89]; while
inAMDitisthoughttobeinvolvedinmicrovesselformation
duringearly phases of angiogenesis, in the reabsorption of-
neovascularization, and in involution and regression of ves-
sels inlater stages [90]. Similarities to the local inﬂamma-
tory components seen in Alzheimer’s also support this the-
ory where accumulations of neuroﬁbrillary tangles or insol-
uble deposits of beta amyloid peptide are the inciting agents
of local inﬂammation [86].
The association between complement factor H (CHF) sin-
gle nucleotide polymorphisms and increased risk of AMD
also uncovers an important link between the complement
system (inﬂammation) and the development of maculopa-
thy (AMD) [18–20, 91]. The gene for CHF is located within
thechromosomalregion(1q32)linkedtoAMD[82,92].The
CHF gene encodes a protein, complement response factor
(CRF), that functions as part of the complement system and
has been found in drusen from AMD patients [82, 93]. Fur-
thermore,thesameenvironmentalriskfactors,smoking,that
inﬂuence levels of complement in serum are also associated
with increased risk of developing AMD [86, 94].
In Alzheimer’s, atherosclerosis, and AMD similar local
proinﬂammatorypathwaysarestimulated,therebyleadingto
the deposition of activated complement components, acute-
phase proteins, and other inﬂammatory mediators in tissues
aﬀected by each disease process. The cumulative impact is
chronic tissue-speciﬁc low-grade inﬂammation exacerbating
the eﬀects of the primary pathogenic lesion [86]. PPARs act
to inhibit many proinﬂammatory genes, which may result in
protection of these diseases.
5. MOLECULES THAT INTERACT WITH
PPAR AND THEIR RELATIONSHIP WITH AMD:
AN INTRODUCTION TO VEGF, MMP, AND DHA
5.1. VascularendothelialgrowthfactorA,VEGF
VEGF was ﬁrst identiﬁed in the early 1970s as a tumor-
angiogenesis factor that is mitogenic to capillary endothelial
cells in human tumors [95]. VEGF is now recognized as an
essential regulator of normal and abnormal vessel growth. It
regulates both vascular proliferation, as well as permeability,
and functions as an antiapoptotic factor for newly formed
bloodvessels[95].VEGF isexpressedin response tohypoxia,
oncogenes, or cytokines [96]. In this process, VEGF binds to
and stimulates autophosphorylation of two distinct receptor
tyrosine kinases, VEGFR1 or Flt-1 (fms-related tyrosine ki-
nase 1) and VEGFR2 or KDR/FlK-1 (kinase insert domain
containing receptor/fetal liver kinase 1) [97]. This activates
anMAPKpathwaycausingneovascularchannelgrowthfrom
the choroidal vasculature and extension into the space be-
tween the RPE and Bruch’s membrane thus activating the
RPEtomigrateintostromaoftheCNVlesion[98,99].VEGF
blockade has been shown to have a direct and rapid anti-
vascular eﬀect in tumors by deprivation of tumor vascular
supply and inhibition of endothelial proliferation. Recently,
VEGFhasalsobeenshowntotargetCNVinAMD[100].The
ﬁrst anti-VEGF compound, pegaptanib, was approved by the
FDA in 2004 and followed closely by approval of two other
treatments, bevacizumab (Avastin) and ranibizumab (Lu-
centis). With monthly intravitreal injections of ranibizumab,
growth of neovascular membranes is halted and there is pre-
vention of severe vision loss in 90% of patients and improve-
ment of visual acuity in 30–40% of patients [101–104].
5.2. Matrixmetalloproteases,MMPs
The regulated turnover of extracellular matrix macro-
molecules is crucial to a variety of important biological
processes. MMPs, a member of the class of proteases, de-
gradecomponentsofextracellularmembranes[105].MMPs,
zinc-dependent endopeptidases, are expressed by activated
macrophage foam cells and smooth muscle cells, and are im-
portant in the resorption of extracellular matrixes in both
physiological and pathological processes. MMPs are secreted
bymacr ophagesasapr oenzymeandonceactivatedcanc om-
pletely degrade extracellular matrix components, such as
elastinandcollagen,includingthestructuralbackboneofthe
basement membrane, type IV collagen. Mostly this group of
enzymes acts locally where they are expressed to aid in cell
migration by clearing a path through the matrix, exposing
cryptic sites on the cleaved proteins that promote cell bind-
ing and/or cell migration, promoting cell detachment so that
a cell can move onward, or by releasing extracellular signal
proteins that stimulate cell migration [105].
MMP-9, a speciﬁc MMP, is thought to degrade the ﬁbri-
nous cap found on atherosclerotic plaques, destabilizing the
plaque, and priming it for rupture [106]. Since AMD is as-
sociated with sustained chronic inﬂammation and loss of in-
tegrity of Bruch’s membrane, it has been hypothesized that
MMPs may play a role in the pathogenesis of the disease
[107]. MMP-9 and MMP-2, two subtypes of MMPs, have
been identiﬁed in Bruch’s membrane in AMD eyes, and cell-
culture studies have documented its role in the development
of CNV [108–110]. A recent study found the ﬁrst associa-
tion between AMD and MMP-9 [108]. Signiﬁcantly elevated
plasma MMP-9 levels were reported in both wet and dry
AMDpatientsascomparedtoage-matchedcontrols.Inaddi-
tion, circulating plasma levels of MMP-9 were approximately
three times higher in AMD patients than in control patients
with no confounding illnesses. MMP transcriptional activ-
ity is regulated by genetic polymorphisms of the promotor6 PPAR Research
region and carriers repeats of the MMP-9 promotor, num-
bering greater than or equal to 22, have a more than dou-
bled risk of developing AMD [37]. Facilitating this MMP-9
expression may act as a factor in increasing vascular perme-
ability of the vessels or in the neovascularization seen in ex-
udative AMD.
5.3. Docosahexaenoicacid,DHA
Docosahexaenoic acid (DHA) is a major dietary omega-3
LCPUFA.Itisalsoamajorstructurallipidofretinalphotore-
ceptor outer segment membranes with the highest concen-
trations per unit weight found here. Omega-3 LCPUFA have
the capacity to play roles in many processes of AMD, such as
retinal neovascularization, inﬂammation of the retinal vas-
culature, and alterations in the retinal capillary structure and
integrity [9]. DHA has been shown to promote survival, in-
hibit apoptosis of photoreceptors, possibly via signaling cas-
cades,playaroleinrhodopsin regeneration,andexertneural
protection through an RPE-secreted neuroprotective media-
tor, NPD-1. Tissue DHA insuﬃciency can aﬀect retinal sig-
naling and is associated with alterations in retinal function
[9]. It has also been documented that there exists an inverse
relationship between dietary intake of the omega-3 LCPUFA
and risk of developing AMD [111].
Despite the beneﬁts of polyunsaturated fatty acids, hu-
mans lack the Δ15 and 12 desaturase enzymes to synthe-
size these compound de novo and are dependent on dietary
sources. In addition, the biochemical nature of DHA and the
proximity of these compounds to metabolically active ocu-
lar tissue and high oxygen tension of the choriocapillaries
facilitate the formation of ROSs. ROSs may start an oxida-
tive cascade altering the DHA and changing the composi-
tion of the cellular membrane and increasing the expression
ofproinﬂammatory genes and cytokines, thereby damaging
the retina [62, 63]. ROS are therefore extremely dangerous
because they damage DHA, a necessary yet limited resource
needed to keep retina healthy.
6. IMPORTANT MOLECULES INVOLVED IN
PPAR’s POTENTIAL ROLE IN AMD
6.1. VEGF,PPARγ,andtheirroleinAMD
As previously discussed, VEGF has been shown to play a crit-
ical role in neovascularization via the MAPK kinase path-
way,associatedwiththewetformofAMD[103,104].PPARγ
with expression localized to the RPE and choroidal endothe-
lial cells of ocular tissue [53] may have an eﬀect on endothe-
lial cells and may have a direct antagonistic relationship with
VEGF.
It has been demonstrated that vascular endothelial cells
express PPAR-γ mRNA and protein [61, 112]. PPAR-γ lig-
ands inhibit growth factor-induced proliferation of endothe-
lial cells, increase plasminogen activator inhibitor-1 expres-
sion and suppress endothelin-1 secretion [113, 114], overall
providing support to the theory that PPAR-γ plays an an-
tagonistic role to that of VEGF [115]. More directly Murata
and colleagues demonstrated that PPARγ inhibits MAPK-
dependent migration of smooth muscle and may act as a
downstream inhibitor to VEGF. This group also showed
that troglitazone and rosiglitazone, synthetic agonists of
PPARγ, inhibited the endothelial eﬀects of VEGF in a dose-
dependent manner. In vivo studies with the troglitazone
demonstrated that intravitreal injections dramatically inhib-
ited the percentage of lesions as well as leakage per lesion,
making a strong case for therapeutic value of this drug [53].
6.2. Matrixmetalloproteinase(MMP),PPARγ,and
theirroleinAMD
Ricote showed that PPARγ inhibits the expression of MMP-
9 in response to a naturally occurring ligand, prostaglandin
D2 metabolite 15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2),
and synthetic PPARγ ligands activated macrophages by an-
tagonizing the activities of the transcription factors AP-1,
STAT, and NF-κB[ 52]. PPARγ activators decrease MMP-
9 expression in vascular smooth muscle [116]a n dt r e a t -
ment with PPAR agonist troglitazone has shown decreased
atheroscleroticlesionsinvariousanimalmodels[107].Inad-
dition PPARγ-mediated suppression of NF-κBa c t i v i t ym a y
decrease proinﬂammatory cytokines in macrophages, in-
cluding MMP-9 [117].
This intricate relationship demonstrates that PPARγ
downregulates MMP expression and inhibits MMP-9’s sub-
sequent accumulation in Bruch’s membrane where it may
play an integral role in the degradation of the extracellu-
lar matrix and be a stimulus for migration of the RPE into
Bruch’s membrane, in this way contributing to the patho-
physiology of AMD.
6.3. DHA,PPARγ,andtheirroleinAMD
DHA is a naturally occurring ligand to all subtypes of the
PPAR family. It binds speciﬁc DNA motifs to modulate the
activity of PPAR and RXR as transcription factors [9]. As
being well known, PPARs play an important regulatory role
in oxidative stress by inducing the transcription of antiox-
idant genes, such as glutamate cysteine ligase (GCL) and
heme oxidase-1 (HO-1) [118]. These antioxidants then work
through MAPK kinase pathways to curb ROS. A functional
PPRE is located at the catalase gene promoter, a gene known
to protect cells from the toxic eﬀects of hydrogen peroxide
(H2O2) bycatalyzingits decomposition, indicating thatcata-
lase expression is directly regulated by PPARγ [62]. To fur-
ther test this relationship, catalase expression was analyzed
in the striatum of rats subjected to intracranial bleeds with
and without 15-dPGJ2 treatment. Treated rats showed 1.6-
, 2.1-, and 1.7 fold higher levels of catalase mRNA expres-
sion compared to the saline controls at 1, 3, and 24 hours
[63]. Girnun et al. found similar increases in catalase mRNA
when using known PPAR agonists rosiglitazone and ciglita-
zone in rat brain microvascular endothelium cells, one of the
cell types damaged during inﬂammatory responses induced
by ROS generation [62].
In short, PPARγ has a special role in counteracting
the damaging eﬀects of ROS generation by upregulat-
ing antioxidant genes and downregulating proinﬂammatoryAlexandra A. Herzlich et al. 7
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Figure 2: Schematic graph showing PPAR interactions with VEGF, ROS, MMP-9, LCPUFA, DHA, and RPE cells and their role in the
development of AMD.
genes. By decreasing damage to LCPUFAs, such as DHA,
there is preservation of the protective eﬀects these essential
molecules confer to the retina.Enhancing this ability of the
RPE to protect itself from oxidative injury may provide a
therapeutic opportunity to delay or hinder the development
of AMD.
7. SUMMARY
Though there is limited literature directly linking PPAR dys-
function with AMD pathology, there is evidence that PPARs
may be involved in various mechanisms and pathways as-
sociated with this disease process. PPARγ is localized to the
neuroretina and RPE, the essential component to photore-
ceptor degeneration and vision loss. PPAR acts to inhibit in-
ﬂammatory processes, which are linked to AMD. VEGF is a
known driving factor for neovascularization, a main causal
element of wet macular degeneration and PPARs directly in-
hibit VEGF function. High levels of MMP-9 have been de-
tected in retinas aﬄicted with AMD. In turn, PPARs are
known to decrease expression of MMP. PPARs play a di-
rect role in upregulation of antioxidative enzymes, one of the
many possible causes of macular pathology. PPARs bind var-
ious ligands including LCPUFAs and their metabolites, pos-
sibly shedding light on how PPARs interfere with NFκBa s
one way in which omega-3 LCPUFAs are protective against
AMD. It is evident that PPARs must play a certain role in the
development of AMD. Figure 2 demonstrates the many ways
that PPARs interact with processes closely related to progres-
sionofAMD.Futurestudiesarewarrantedtobetterelucidate
the pathogenic and therapeutic potentials of PPARs in AMD.
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